Mammalian target of rapamycin (mTOR) inhibitors and combined chemotherapy in breast cancer: A meta-analysis of randomized controlled trials

International Journal of Clinical and Experimental Medicine

Volumn 7, Issue 10, 2014, Pages 3333-3343

  Qiao, Longwei ^a   Liang, Yuting ^a   Mira, Ranim R ^b   Lu, Yaojuan ^a,b   Gu, Junxia ^a   Zheng, Qiping ^a,b  

^a JIANGSU UNIVERSITY   (China)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aromatase inhibitors; Breast cancer; Chemotherapy; Meta analysis; mTOR inhibitors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; EXEMESTANE; HORMONE RECEPTOR; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PLACEBO; RAPAMYCIN; TEMSIROLIMUS;

ANOREXIA; ARTICLE; BIBLIOGRAPHIC DATABASE; BREAST METASTASIS; CANCER CHEMOTHERAPY; CLINICAL ASSESSMENT; CONFIDENCE INTERVAL; DIARRHEA; FATIGUE; HUMAN; HYPERGLYCEMIA; INFORMATION PROCESSING; META ANALYSIS; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; POSTMENOPAUSE; PROGRESSION FREE SURVIVAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; RASH; STOMATITIS;

EID: 84910067484     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Wullschleger S, Loewith R and Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124: 471-484.
2. Laplante M and Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149: 274-293.
3. Vinayak S and Carlson RW. mTOR inhibitors in the treatment of breast cancer. Oncology (Williston Park) 2013; 27: 38-44, 46, 48 passim.
4. Lbanell J, Dalmases A, Rovira A and Rojo F. mTOR signalling in human cancer. Clin Transl Oncol 2007; 9: 484-493.
5. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
6. Rimawi MF and Osborne CK. Breast Cancer: Blocking both driver and escape pathways improves outcomes. Nat Rev Clin Oncol 2012; 9: 133-134.
7. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378: 771-784.
8. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA, Wolmark N. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2012; 9: 3366-3373.
9. Paplomata E and O'Regan R. New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus. Ther Clin Risk Manag 2013; 9: 27-36.
10. Rugo HS and Keck S. Reversing hormone resistance: have we found the golden key? J Clin Oncol 2012; 30: 2707-2709.
11. Dhillon S. Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced bre-ast cancer. Drug 2013; 73: 475-485.
12. Shtivelband MI. Everolimus in hormone receptor-positive advanced breast cancer: targeting receptor-based mechanisms of resistance. Breast 2013; 22: 405-410.
13. Zagouri F, Sergentanis TN, Chrysikos D, Filipits M and Bartsch R. mTOR inhibitors in breast cancer: a systematic review. Gynecol Oncol 2012; 127: 662-672.
14. Leung HW and Chan AL. Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis. Clin The 2011; 33: 708-716.
15. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
16. Kjaergard LL, Villumsen J and Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001; 135: 982-989.
17. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366: 520-529.
18. Campone M, Bachelot T, Gnant M, Deleu I, Rugo HS, Pistilli B, Noguchi S, Shtivelband M, Pritchard KI, Provencher L, Burris HA 3rd, Hart L, Melichar B, Hortobagyi GN, Arena F, Baselga J, Panneerselvam A, Héniquez A, El-Hashimyt M, Taran T, Sahmoud T, Piccart M. Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. Eur J Cancer 2013; 49: 2621-2632.
19. Hortobagyi GN, Piccart M, Rugo H, Burris H, Campone M, Noguchi S, Gnant M, Pritchard KI, Vittori L, Mukhopadhyay P, Sahmoud T, Lebwohl D, Baselga J. Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial. Cancer Res 2011; 71 Suppl 24: Abstract nr S3-7.
20. Noguchi S, Masuda N, Iwata H, Mukai H, Horiguchi J, Puttawibul P, Srimuninnimit V, Tokuda Y, Kuroi K, Iwase H, Inaji H, Ohsumi S, Noh WC, Nakayama T,Ohno S, Rai Y, Park BW, Panneerselvam A, El-Hashimy M, Taran T, Sahmoud T, Ito Y. Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2. Breast Cancer 2013; [Epub ahead of print].
21. Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaëth D, Legouffe E, Allouache D, El Kouri C, Pujade-Lauraine E. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012; 30: 2718-2724.
22. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009; 27: 2630-2637.
23. Huober J, Fasching PA, Hanusch C, Rezai M, Eidtmann H, Kittel K, Hilfrich J, Schwedler K, Blohmer JU, Tesch H, Gerber B, Höß C, Kümmel S, Mau C, Jackisch C, Khandan F, Costa SD, Krabisch P, Loibl S, Nekljudova V, Untch M, Minckwitz Gv. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab- results of the randomised GeparQuinto study (GBG 44). Eur J Cancer 2013; 49: 2284-2293.
24. Chow LWC, Sun Y, Jassem J, Baselga J, Hayes DF, Wolff AC, Hachemi S, Cincotta M, Yu BW, Kong S, Moore L. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2006; 100 (suppl 1): 6091.
25. Wolff AC, Lazar AA, Bondarenko I, Garin AM, Brincat S, Chow L, Sun Y, Neskovic-Konstantinovic Z, Guimaraes RC, Fumoleau P, Chan A, Hachemi S, Strahs A, Cincotta M, Berkenblit A, Krygowski M, Kang LL, Moore L, Hayes DF. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2013; 31: 195-202.
26. Bhattacharvva GS, Biswas J, Singh JK, Singh M, Govindbabu K, Ranade AA, Malotra H, Parikh PM, Shahid T, Basu S. Reversal of tamoxifen resistance (hormone resistance) by addition of sirolimus (mTOR inhibitor) in metastatic breast cancer. Eur J Cancer 2011; 47: 9.
27. Villarreal-Garza C, Cortes J, Andre F and Verma S. mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions. Ann Oncol 2012; 23: 2526-2535.
28. Porta C, Osanto S, Ravaud A, Climent MA, Vaishampayan U, White DA, Creel P, Dickow B, Fischer P, Gornell SS, Meloni F, Motzer RJ. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 2011; 47: 1287-1298.
29. Shao N, Wang S, Yao C, Xu X, Zhang Y, Zhang Y, Lin Y. Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: a meta-analysis of phase III randomized control trials. Breast 2012; 21: 389-393.
30. Margariti N, Fox SB, Bottini A and Generali D. "Overcoming breast cancer drug resistance with mTOR inhibitors". Could it be a myth or a real possibility in the short-term future? Breast Cancer Res Treat 2011; 128: 599-606.